ArticleFrontiers in endocrinology2026
Early insulin combined with metformin therapy and long-term risks of cardiovascular disease, kidney disease, and cancer in newly diagnosed type 2 diabetes: a real-world cohort study in China.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the longitudinal associations of early insulin combined with metformin therapy, compared with metformin monotherapy, with subsequent risks of stroke, heart failure, chronic kidney disease, and cancer among adults with newly diagnosed type 2 diabetes using real-world data. Methods: We conducted an active-comparator new-user cohort study using the Cheeloo LEAD electronic health record database (Shandong, China; 2014-2021). Adults aged 40-85 years who initiated early insulin combined with metformin therapy or metformin monotherapy during 2014-2017 were included in the common parent cohort (n=19,908; 4,304 [21.6%] and 15,604 [78.4%], respectively). Follow-up began at each treatment strategy initiation date (t0). Four independent outcome-specific subcohorts excluded patients with the corresponding pre-existing outcome and those with the outcome recorded within 30 days after t0. The combination group required at least 14 days of overlapping insulin and metformin use. L1-regularized propensity score matching and Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) over up to 1,500 days. Sensitivity analyses used a 180-day outcome-exclusion window. Results: Compared with metformin monotherapy, early insulin combined with metformin therapy was associated with a lower hazard of stroke (HR 0.88, 95% CI 0.78-0.99) and higher hazards of heart failure (HR 1.18, 95% CI 1.02-1.36), chronic kidney disease (HR 1.37, 95% CI 1.03-1.83), and cancer (HR 1.37, 95% CI 1.14-1.66). Exploratory subgroup estimates varied by age and sex; no formal interaction tests were performed. Results were broadly consistent in sensitivity analyses. Conclusion: Early insulin combined with metformin therapy and metformin monotherapy showed different longitudinal associations with the four outcomes. These findings should be interpreted in light of residual confounding by baseline disease severity and treatment indication and may inform risk monitoring in routine care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.